# Alivus Life Sciences Limited (ALIVUS)

> ALIVUS closed at ₹1,415.30 on 30 Oct 2026, trailing P/E 25.9, market cap ₹17,376 cr, latest results for the quarter ended 30 Sept 2026. Revenue, profit, ROE, debt, own P/E range and sector-peer comparison from the SEBI filing.

Alivus Life Sciences Limited (NSE: ALIVUS) closed at ₹1,415.30 on 30 Oct 2026, +53.3% over one year, against a 52-week range of ₹819.00 – ₹1,499.00.

In the quarter ended 30 Sept 2026 (standalone, filed 29 Oct 2026) it reported revenue of ₹682 cr and net profit of ₹197 cr, a 28.9% net margin; revenue grew 16.0% and profit grew 50.4% year on year.

On four consecutive filed quarters its trailing P/E is 25.9; since 15 May 2025 its own P/E has ranged from 19.4 to 30.4 (median 23.8), and today's reading is higher than 77% of those 361 trading days.

From the balance sheet dated 30 Sept 2026: return on equity 21.7%, ROCE 27.9%, debt-to-equity 0.00, Piotroski F-score 8 of 9.

Against 66 Healthcare peers on NSE: Net margin higher than 95% of 64 sector peers; PBT margin higher than 98% of 64 sector peers; ROE higher than 80% of 64 sector peers.

## Key figures

| Figure | Value |
|---|---|
| Last close | ₹1,415.30 (30 Oct 2026) |
| Change 1 month / 6 months / 1 year | +3.3% / +34.8% / +53.3% |
| 52-week low – high | ₹819.00 – ₹1,499.00 |
| Market capitalisation | ₹17,376 cr |
| Trailing P/E | 25.9 |
| Price / book | 4.78 |
| EV / EBITDA | 17.8 |
| Earnings yield | 3.9% |
| TTM EPS | ₹54.55 |
| TTM net profit | ₹670 cr |
| Quarter revenue | ₹682 cr |
| Quarter net profit | ₹197 cr |
| Net margin | 28.9% |
| Revenue growth (YoY) | +16.0% |
| Profit growth (YoY) | +50.4% |
| Return on equity | 21.7% |
| ROCE | 27.9% |
| Debt / equity | 0.00 |
| Current ratio | 5.08 |
| Free cash flow | ₹270 cr |
| Piotroski F-score | 8 / 9 |
| Average daily turnover (50 days) | ₹11.4 cr |

## Questions

### What is the P/E ratio of Alivus Life Sciences Limited?

Alivus Life Sciences Limited's trailing P/E is 25.9, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Sept 2026. Since 15 May 2025 its P/E has ranged 19.4–30.4.

### What were Alivus Life Sciences Limited's latest quarterly results?

For the quarter ended 30 Sept 2026, Alivus Life Sciences Limited reported revenue of ₹682 cr and net profit of ₹197 cr (standalone), filed with the exchange on 29 Oct 2026.

### What is Alivus Life Sciences Limited's ROE?

Return on equity is 21.7% based on the balance sheet dated 30 Sept 2026.

### Does Alivus Life Sciences Limited have debt?

Debt-to-equity is 0.00 on the balance sheet dated 30 Sept 2026.

### What is ALIVUS's 52-week high and low?

Over the last 52 weeks to 30 Oct 2026, ALIVUS traded between ₹819.00 and ₹1,499.00.

Sector: [Healthcare](https://trinetra.trade/sectors/healthcare) · Page: https://trinetra.trade/fundamentals/ALIVUS

_TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing._